The EDGE

Professor David Grimwade (1962–2016)

N H Russell, S D Freeman and C Craddock

Bone Marrow Transplant 2017 52: 171-172; advance online publication, January 16, 2017; 10.1038/bmt.2016.350

Reviews

Metabolic syndrome and cardiovascular disease following hematopoietic cell transplantation: screening and preventive practice recommendations from CIBMTR and EBMT

Z DeFilipp, R F Duarte, J A Snowden, N S Majhail, D M Greenfield, J L Miranda, M Arat, K S Baker, L J Burns, C N Duncan, M Gilleece, G A Hale, M Hamadani, B K Hamilton, W J Hogan, J W Hsu, Y Inamoto, R T Kamble, M T Lupo-Stanghellini, A K Malone, P McCarthy, M Mohty, M Norkin, P Paplham, M Ramanathan, J M Richart, N Salooja, H C Schouten, H Schoemans, A Seber, A Steinberg, B M Wirk, W A Wood, M Battiwalla, M E D Flowers, B N Savani and B E Shaw on behalf of the CIBMTR Late Effects and Quality of Life Working Committee and the EBMT Complications and Quality of Life Working Party

Bone Marrow Transplant 2017 52: 173-182; advance online publication, August 22, 2016; 10.1038/bmt.2016.203

Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation

J Whangbo, J Ritz and A Bhatt

Bone Marrow Transplant 2017 52: 183-190; advance online publication, August 15, 2016; 10.1038/bmt.2016.206

Special Report

Impact of drug development on the use of stem cell transplantation: a report by the European Society for Blood and Marrow Transplantation (EBMT)

J R Passweg, H Baldomero, P Bader, C Bonini, S Cesaro, P Dreger, R F Duarte, C Dufour, J Kuball, D Farge-Bancel, A Gennery, N Kröger, F Lanza, A Nagler, A Sureda and M Mohty for the European Society for Blood and Marrow Transplantation (EBMT)

Bone Marrow Transplant 2017 52: 191-196; advance online publication, November 7, 2016; 10.1038/bmt.2016.258

Commentaries

Therapy of pediatric ALL relapsing after allogeneic transplant: how to make progress with limited patient numbers?

M Bierings

Bone Marrow Transplant 2017 52: 197-198; advance online publication, November 28, 2016; 10.1038/bmt.2016.276

Diffuse large B-cell lymphoma: the challenge of relapse after an autologous stem cell transplant

S P Robinson

Bone Marrow Transplant 2017 52: 199-200; advance online publication, November 21, 2016; 10.1038/bmt.2016.292

Original Articles

ACUTE LEUKEMIA

Treatment of relapse after allogeneic stem cell transplantation in children and adolescents with ALL: the Frankfurt experience

A M Willasch, E Salzmann-Manrique, T Krenn, M Duerken, J Faber, J Opper, H Kreyenberg, R Bager, S Huenecke, C Cappel, M Bremm, V Pfirrmann, M Merker, E Ullrich, S Bakhtiar, E Rettinger, A Jarisch, J Soerensen, T E Klingebiel and P Bader

Bone Marrow Transplant 2017 52: 201-208; advance online publication, September 19, 2016; 10.1038/bmt.2016.224

Allogeneic haematopoietic stem cell transplant in patients with lower risk myelodysplastic syndrome: a retrospective analysis on behalf of the Chronic Malignancy Working Party of the EBMT

M Robin, R Porcher, W Zinke-Cerwenka, A van Biezen, L Volin, G Mufti, C Craddock, J Finke, C Richard, J Passweg, A Peniket, J Maertens, G Sucak, T Gedde-Dahl, A Vitek, A Nagler, D Blaise, D Beelen, N Maillard, R Schwerdtfeger, T de Witte and N Kroger

Bone Marrow Transplant 2017 52: 209-215; advance online publication, November 7, 2016; 10.1038/bmt.2016.266

LYMPHOMA

Outcomes of diffuse large B-cell lymphoma patients relapsing after autologous stem cell transplantation: an analysis of patients included in the CORAL study

E Van Den Neste, N Schmitz, N Mounier, D Gill, D Linch, M Trneny, R Bouadballah, J Radford, M Bargetzi, V Ribrag, U Dührsen, D Ma, J Briere, C Thieblemont, E Bachy, C H Moskowitz, B Glass and C Gisselbrecht

Bone Marrow Transplant 2017 52: 216-221; advance online publication, September 19, 2016; 10.1038/bmt.2016.213

PLASMA CELL DISORDERS

Peripheral blood stem cell mobilization in multiple myeloma comparison of two consecutive regimens in a limited resources country

N Ben Abdejlil, D Belloumi, M Mâammar, R El Fatimi, L Torjman, A Lakhal, F Jenhani, S Hmida, T Ben Othman and S Ladeb

Bone Marrow Transplant 2017 52: 222-227; advance online publication, October 24, 2016; 10.1038/bmt.2016.246

Efficacy of host-dendritic cell vaccinations with or without minor histocompatibility antigen loading, combined with donor lymphocyte infusion in multiple myeloma patients

R Oostvogels, E Kneppers, M C Minnema, R C Doorn, L E Franssen, T Aarts, M E Emmelot, E Spierings, I Slaper-Cortenbach, K Westinga, E Goulmy, H M Lokhorst and T Mutis

Bone Marrow Transplant 2017 52: 228-237; advance online publication, November 14, 2016; 10.1038/bmt.2016.250

CONDITIONING

Safety and efficacy of thiotepa-based conditioning for allogeneic transplantation in AML: a survey from the ALWP of the EBMT

S Eder, M Labopin, J Finke, D Bunjes, A Olivieri, S Santarone, A Rambaldi, L Kanz, G Messina, M Mohty and A Nagler on behalf of the ALWP of the EBMT

Bone Marrow Transplant 2017 52: 238-244; advance online publication, September 19, 2016; 10.1038/bmt.2016.239

TRANSPLANT TOXICITIES

Thrombomodulin blocks calcineurin inhibitor-induced vascular permeability via inhibition of Src/VE-cadherin axis

T Ikezoe, J Yang, C Nishioka, K Umezawa and A Yokoyama

Bone Marrow Transplant 2017 52: 245-251; advance online publication, September 19, 2016; 10.1038/bmt.2016.241

GRAFT-VERSUS-HOST DISEASE

Low-dose thymoglobulin as second-line treatment for steroid-resistant acute GvHD: an analysis of the JSHCT

M Murata, K Ikegame, Y Morishita, H Ogawa, K Kaida, H Nakamae, T Ikeda, T Nishida, M Inoue, T Eto, K Kubo, T Sakura, T Mori, N Uchida, T Ashida, Y Matsuhashi, Y Miyazaki, T Ichinohe, Y Atsuta and T Teshima

Bone Marrow Transplant 2017 52: 252-257; advance online publication, November 21, 2016; 10.1038/bmt.2016.247

DONOR SAFETY

Predictors of general discomfort, limitations in activities of daily living and intention of a second donation in unrelated hematopoietic stem cell donation

M H Lee, J H Jang, H J Min, H I Jang, J H Nah, C J Lyu, K-S Han, J H Won, Y-H Lee, S Y Chong, Y C Mun, W S Lee, S J Kim and I Kim

Bone Marrow Transplant 2017 52: 258-263; advance online publication, November 7, 2016; 10.1038/bmt.2016.260

INFECTIONS

Association of Epstein–Barr virus reactivation with the recovery of CD4/CD8 double-negative T lymphocytes after haploidentical hematopoietic stem cell transplantation

Z Bian, J Liu, L-P Xu, Y-J Chang, Y Wang, X-H Zhang and X-J Huang

Bone Marrow Transplant 2017 52: 264-269; advance online publication, October 31, 2016; 10.1038/bmt.2016.238

Pre-existing invasive fungal infection is not a contraindication for allogeneic HSCT for patients with hematologic malignancies: a CIBMTR study

R T Maziarz, R Brazauskas, M Chen, A A McLeod, R Martino, J R Wingard, M Aljurf, M Battiwalla, C C Dvorak, B Geroge, E C Guinan, G A Hale, H M Lazarus, J-W Lee, J L Liesveld, M Ramanathan, V Reddy, B N Savani, F O Smith, L Strasfeld, R A Taplitz, C Ustun, M J Boeckh, J Gea-Banacloche, C A Lindemans, J J Auletta and M L Riches

Bone Marrow Transplant 2017 52: 270-278; advance online publication, December 19, 2016; 10.1038/bmt.2016.259

QOL AND PATIENTS' CARE

Cognitive problems following hematopoietic stem cell transplant: relationships with sleep, depression and fatigue

S E Ghazikhanian, C S Dorfman, T J Somers, M L O'Sullivan, H M Fisher, S N Edmond, A A Wren, S A Kelleher, K A Rowe Nichols, N Chao and R A Shelby

Bone Marrow Transplant 2017 52: 279-284; advance online publication, December 12, 2016; 10.1038/bmt.2016.248

Preliminary efficacy of a brief family intervention to prevent declining quality of life secondary to parental bone marrow transplantation

B L Fife, D M Von Ah, M L Spath, M T Weaver, Z Yang, T Stump and S Farag

Bone Marrow Transplant 2017 52: 285-291; advance online publication, November 21, 2016; 10.1038/bmt.2016.267

CLINICAL TRIAL DESIGN

A qualitative exploration of the informed consent process in hematopoietic cell transplantation clinical research and opportunities for improvement

M Raj, S W Choi and J Platt

Bone Marrow Transplant 2017 52: 292-298; advance online publication, October 17, 2016; 10.1038/bmt.2016.252

Letters to the Editor

Cyclophosphamide vs salvage chemotherapy plus G-CSF as chemo-mobilization in Asian patients undergoing autologous hematopoietic stem cell transplant OPEN

S Issaragrisil, T Cheng-Hwai, U Bunworasate, Y Su-Peng, L Y Hung, G Y Tee, S F A Wahid, N S Chin, T Puavilai, G G Gin, K L Piu, H Wen-Li, C Tsai-Yun and T Numbenjapon

Bone Marrow Transplant 2017 52: 299-300; advance online publication, November 14, 2016; 10.1038/bmt.2016.245

Low day +100 serum epidermal growth factor levels are associated with acute GvHD after allogeneic hematopoietic cell transplantation

F He, M R Verneris, S Cooley, B R Blazar, M L MacMillan, L F Newell, A Panoskaltsis-Mortari, T DeFor, D J Weisdorf and S G Holtan

Bone Marrow Transplant 2017 52: 301-303; advance online publication, November 21, 2016; 10.1038/bmt.2016.261

Medication nonadherence to immunosuppressants after adult allogeneic haematopoietic stem cell transplantation: a multicentre cross-sectional study

B Gresch, M Kirsch, K Fierz, J P Halter, G Nair, K Denhaerynck and S De Geest

Bone Marrow Transplant 2017 52: 304-306; advance online publication, November 14, 2016; 10.1038/bmt.2016.262

Danaparoid reduces the incidence of hematopoietic stem cell transplantation-associated thrombotic microangiopathy

S Machida, M Onizuka, M Toyosaki, Y Aoyama, H Kawai, J Amaki, R Hara, A Ichiki, Y Ogawa, H Kawada and K Ando

Bone Marrow Transplant 2017 52: 307-309; advance online publication, November 28, 2016; 10.1038/bmt.2016.270

First-line escalated BEACOPP does not hinder stem cell collection and transplantation strategy in patients with relapsed/refractory Hodgkin’s lymphoma

D Ghez, C Fortpied, N Mounier, P Carde, A Perrot, H Khaled, S Amorim, S Ramadan, F L Bras, M Erlanson, C Herbaux, J-P Marolleau, E Nicolas-Virelezier, O Casasnovas, A Stamatoullas-Bastard and C Fermé on behalf of EORTC, LYSA, LYMG and NLG cooperating groups

Bone Marrow Transplant 2017 52: 310-312; advance online publication, November 28, 2016; 10.1038/bmt.2016.271

Anti-Muellerian hormone (AMH) as only possible marker in the assessment of ovarian function and reserve after hematopoietic stem cell transplantation (HSCT) in prepubertal girls, young females with composed hypogonadism and females receiving hormonal replacement therapy

A Wędrychowicz, J Wojtyś and J Starzyk

Bone Marrow Transplant 2017 52: 313-316; advance online publication, November 14, 2016; 10.1038/bmt.2016.273

PD-1 checkpoint blockade in patients with relapsed AML after allogeneic stem cell transplantation

J C Albring, S Inselmann, T Sauer, C Schliemann, B Altvater, S Kailayangiri, C Rössig, W Hartmann, J R Knorrenschild, K Sohlbach, C Groth, M Lohoff, A Neubauer, W E Berdel, A Burchert and M Stelljes

Bone Marrow Transplant 2017 52: 317-320; advance online publication, November 28, 2016; 10.1038/bmt.2016.274

Long-term outcomes after thiotepa-based high-dose therapy (HDT) and autologous hematopoietic cell transplantation (auto-HCT) in non-Hodgkin lymphoma (NHL)

N Shah, S Rauenzahn, L Veltri, S Wen, M Craig, M Hamadani, A S Kanate and A Cumpston

Bone Marrow Transplant 2017 52: 321-322; advance online publication, November 28, 2016; 10.1038/bmt.2016.275

Prior history of HLA-mismatched stem cell transplantation is a risk factor for graft failure in HLA-haploidentical transplantation

J Sugita, T Miyamoto, N Kawashima, N Hatsumi, N Anzai, H Kaneko, M Nara, K Minauchi, M Harada and T Teshima on behalf of the Japan Study Group for Cell Therapy and Transplantation (JSCT)

Bone Marrow Transplant 2017 52: 323-325; advance online publication, November 7, 2016; 10.1038/bmt.2016.278

Serum galactomannan surveillance may be safely withdrawn from antifungal management of hematology patients on effective antimold prophylaxis: a pilot single-center study

R F Duarte, I Sánchez-Ortega, M Arnan, B Patiño, J Ayats, A Sureda and M Cuenca-Estrella

Bone Marrow Transplant 2017 52: 326-329; advance online publication, October 31, 2016; 10.1038/bmt.2016.279

Successful haploidentical stem cell transplantation for three adults with primary hemophagocytic lymphohistiocytosis

Z Li, Y Wang, J Wang, J Zhang and Z Wang

Bone Marrow Transplant 2017 52: 330-333; advance online publication, October 24, 2016; 10.1038/bmt.2016.284

Comparison of three or fewer high-dose chemotherapy cycles as salvage treatment in germ cell tumors in first relapse

F Gössi, M Spahn, M Zweifel, S Panagiotis, A Mischo, F Stenner, U Hess, D Berthold, M Bargetzi, J Schardt and T Pabst

Bone Marrow Transplant 2017 52: 334-336; advance online publication, November 28, 2016; 10.1038/bmt.2016.285

A proposed biology- and biomarker-based algorithm for management of acute GvHD

A M Ali, J F DiPersio and M A Schroeder

Bone Marrow Transplant 2017 52: 337-340; advance online publication, November 21, 2016; 10.1038/bmt.2016.289